Emmaus Life Sciences, Inc. (OTCMKTS:EMMA – Get Free Report) was the recipient of a large increase in short interest in August. As of August 31st, there was short interest totaling 21,539 shares, an increase of 610.2% from the August 15th total of 3,033 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average trading volume of 885,605 shares, the short-interest ratio is presently 0.0 days.
Emmaus Life Sciences Stock Performance
Shares of OTCMKTS EMMA remained flat at $0.05 during mid-day trading on Friday. Emmaus Life Sciences has a fifty-two week low of $0.01 and a fifty-two week high of $0.09. The company has a market capitalization of $3.62 million, a price-to-earnings ratio of -0.57 and a beta of 10.07. The firm’s 50 day moving average price is $0.03 and its 200 day moving average price is $0.02.
Emmaus Life Sciences (OTCMKTS:EMMA – Get Free Report) last posted its earnings results on Friday, August 14th. The company reported $0.02 earnings per share for the quarter. The business had revenue of $6.32 million for the quarter.
Emmaus Life Sciences Company Profile
Emmaus Life Sciences, Inc is a publicly traded specialty pharmaceutical company focused on the development and commercialization of therapies for sickle cell disease and other serious hematological disorders. Its lead product, Endari® (L-glutamine oral powder), received U.S. Food and Drug Administration approval in 2017 for reducing the acute complications of sickle cell disease in patients aged five years and older. Through targeted research and development, Emmaus is also advancing additional pipeline candidates aimed at addressing oxidative stress and protein aggregation pathways that underlie various blood disorders.
Emmaus markets Endari in the United States and has entered into licensing agreements to distribute the therapy in regions including sub-Saharan Africa, the Middle East, North Africa and Latin America.
Further Reading
- Five stocks we like better than Emmaus Life Sciences
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
- American Eagle Goes on Sale: Is It Time to Buy?
Receive News & Ratings for Emmaus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emmaus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
